Literature DB >> 23844651

Relationship of testis size and LH levels with incidence of major adverse cardiovascular events in older men with sexual dysfunction.

Giulia Rastrelli1, Giovanni Corona, Francesco Lotti, Valentina Boddi, Edoardo Mannucci, Mario Maggi.   

Abstract

INTRODUCTION: Measurement of testis volume (TV) is a reliable clinical procedure that predicts reproductive fitness. However, the role of TV in overall and cardiovascular (CV) fitness has never been studied. AIM: The study aims to analyze the clinical correlates of TV in patients with sexual dysfunction (SD) and to verify the value of this parameter and its determinants (i.e., luteinizing hormone [LH] levels) in predicting major adverse CV events (MACE).
METHODS: A consecutive series of 2,809 subjects without testiculopathy (age 51.2 ± 13.1) consulting for SD was retrospectively studied. A subset of this sample (n=1,395) was enrolled in a longitudinal study. MAIN OUTCOME MEASURES: Several clinical and biochemical parameters were investigated.
RESULTS: After adjusting for confounders, TV was negatively associated with both LH (Adj. r=-0.234; P<0.0001) and follicle-stimulating hormone (Adj. r=-0.326; P<0.0001). In addition, overweight/obesity, smoking, and alcohol abuse increased as a function of TV (hazard ratio [HR]=1.041 [1.021-1.061], P<0.0001; 1.024 [1.005-1.044], P=0.012; 1.063 [1.015-1.112], P=0.009, respectively). Furthermore, mean blood pressure was positively related to increased TV (Adj. r=0.157; P<0.0001). The effect of these lifestyle factors on TV were only partially related to changes in gonadotropin levels. In the longitudinal analysis, after adjusting for confounders, TV was associated with a higher incidence of MACE (HR=1.066 [1.013-1.122]; P=0.014), and the stepwise introduction in the Cox model of lifestyle factors, mean blood pressure and body mass index progressively smoothed out the association, which was no longer statistically significant in the fully adjusted model. Conversely, the association of higher LH levels with increased incidence of MACE was not attenuated by the progressive introduction of the aforementioned confounders in the model.
CONCLUSIONS: Our data show that in SD subjects, TV and LH are associated with an adverse CV risk profile that mediate the higher TV-associated incidence of MACE. High LH levels are an independent marker of CV risk. Further studies are needed for clarifying determinants and mechanisms of testis enlargement that, beyond gonadotropins, could mediate the increased incidence of MACE.
© 2013 International Society for Sexual Medicine.

Entities:  

Keywords:  Cardiovascular Events; Hypertension; Luteinizing Hormone; Testis Volume; Testosterone

Mesh:

Year:  2013        PMID: 23844651     DOI: 10.1111/jsm.12270

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  4 in total

1.  Testosterone levels after treatment with urofollitropin in infertile patients with idiopathic mild reduction of testicular volume.

Authors:  Sandro La Vignera; Rosita A Condorelli; Rossella Cannarella; Laura Cimino; Laura Mongioi'; Ylenia Duca; Filippo Giacone; Aldo E Calogero
Journal:  Endocrine       Date:  2019-06-25       Impact factor: 3.633

Review 2.  Review of Azoospermia.

Authors:  Matthew Wosnitzer; Marc Goldstein; Matthew P Hardy
Journal:  Spermatogenesis       Date:  2014-03-31

3.  Larger Testicular Volume Is Independently Associated with Favorable Indices of Lung Function.

Authors:  Tae Beom Kim; I Nae Park
Journal:  Tuberc Respir Dis (Seoul)       Date:  2017-09-01

4.  Testicular volume in infertile versus fertile white-European men: a case-control investigation in the real-life setting.

Authors:  Luca Boeri; Paolo Capogrosso; Eugenio Ventimiglia; Walter Cazzaniga; Edoardo Pozzi; Federico Belladelli; Filippo Pederzoli; Massimo Alfano; Costantino Abbate; Emanuele Montanari; Luca Valsecchi; Enrico Papaleo; Paola Viganò; Patrizia Rovere-Querini; Suks Minhas; Francesco Montorsi; Andrea Salonia
Journal:  Asian J Androl       Date:  2021 Sep-Oct       Impact factor: 3.285

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.